SkyePharma/Mundipharma's Flutiform launched in Germany

23 September 2012

UK-based drug delivery specialist SkyePharma (LSE: SKP) last Friday announced the launch of Flutiform, an inhaled combination of fluticasone and formoterol for the treatment of asthma, in Germany by partner Mundipharma, a privately-held Swiss company. The drug was approved by the European Commission during the summer (The Pharma Letter July 4).

Following the launch of Flutiform in Germany, a milestone of 4.0 million euros ($5.3 million) is due to SkyePharma. Half of this amount will be allocated as a prepayment of the Paul Capital Note.

The German launch marks the first European country where Flutiform can be prescribed for appropriate patients with asthma. Marketing authorisations have already been granted in Austria, Cyprus, Germany, Norway, The Netherlands, Slovakia, Sweden and the UK. The Netherlands and UK are due to launch imminently, with further national approvals and subsequent launches are expected across a number of European countries later in 2012 and 2013.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK